Bupropion for the Treatment of Methamphetamine Dependence - 1

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Amphetamine-Related Disorders

Treatments: Drug: Bupropion

Study type: Interventional

Funder types: NIH

Identifiers

NCT00069251

NIDA-CTO-0008-1

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Full description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
• Subject must be willing to comply with study procedures.
• Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
• Be able to comply with protocol requirements

Exclusion criteria

• Please contact site for more information.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind